What is the recommended treatment alternative for persistent mild asthma in children aged 12 and above?

The recommended treatment alternative for persistent mild asthma in children aged 12 and above involves the use of medications such as Cromolyn or Nedocromil. These medications are classified as leukotriene modifiers and mast cell stabilizers, which can help in preventing asthma symptoms by inhibiting the release of inflammatory mediators from mast cells. This can be particularly essential in the management of mild persistent asthma where interventions are aimed at controlling symptoms and preventing exacerbations.

In children aged 12 and older, these medications can be used as an alternative when low-dose inhaled corticosteroids (ICS) are not suitable or tolerated. They are especially beneficial as they are often well-tolerated with a favorable safety profile, making them an appropriate choice in this age group.

While other treatments such as high-dose ICS and biologics like Omalizumab are effective for more severe asthma cases, they are not typically the first-line alternatives for persistent mild asthma. Short-acting beta-agonists (SABAs) are primarily used for quick relief rather than as maintenance therapy, thus making Cromolyn or Nedocromil the more appropriate choices for managing this specific category of asthma in children.